

Supplementary Table 4 Characteristics of the COVID-19 patients with or without PACS at 3 months and 6 months follow-up

	Month 3		Month 6	
	PACS	No PACS	PACS	No PACS
Patients, n	86	20	81	25
Female, n (%)	46 (53.5)	10 (50.0)	46 (56.8)	10 (40.0)
Age, years (IQR)	48.9 (34 - 63)	45.5 (33- 56)	48.7 (33 - 62)	47.9 (33 - 60)
Non-smokers, n (%)	51 (59.3)	10 (50.0)	47 (58.0)	14 (46.0)
Presence of any co-morbidities, n (%)	39 (45.3)	6 (30.0)	36 (44.4)	9 (36.0)
Types of co-morbidities				
Diabetes Mellitus	14 (16.3)	2 (10.0)	13 (16.0)	3 (12.0)
Hypertension	16 (18.6)	2 (10.0)	15 (18.5)	3 (12.0)
Hyperlipidaemia	8 (9.3)	4 (20.0)	7 (8.6)	5 (20.0)
Length of stay in hospital, days (IQR)	18.7 (10 - 25)	15.3 (8 - 19)	18.1 (9 - 23)	16.4 (10 - 25)
Severity of COVID-19, n (%)				
Asymptomatic	4 (4.6)	0 (0)	4 (4.9)	0 (0)
Mild	23 (26.7)	8 (40.0)	23 (28.4)	8 (32.0)
Moderate	47 (54.7)	8 (40.0)	42 (51.9)	13 (52.0)
Severe	7 (8.1)	3 (15.0)	7 (8.6)	3 (12.0)
Critical	5 (5.8)	1 (5.0)	5 (6.2)	1 (4.0)
Treatment for COVID-19, n (%)				
Lopinavir/Ritonavir	50 (0.58)	6 (0.3)	43 (0.53)	13 (0.52)
Ribavirin	39 (0.45)	7 (0.35)	37 (0.45)	9 (0.36)
Interferon	37 (0.43)	7 (0.35)	33 (0.41)	11 (0.44)
Remedesvir	5 (0.06)	1 (0.05)	4 (0.05)	2 (0.08)
Antibiotics	21 (0.24)	4 (0.2)	17 (0.21)	8 (0.32)